Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001209191-16-141648)

Filing Details

Accession Number:
0001209191-16-141648
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-15 18:25:39
Reporting Period:
2016-09-13
Filing Date:
2016-09-15
Accepted Time:
2016-09-15 18:25:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131324 Genomic Health Inc GHDX Services-Medical Laboratories (8071) 770552594
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1337334 Steven Shak 301 Penobscot Drive
Redwood City CA 94063		 Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-13 5,000 $18.89 332,207 No 4 M Direct
Common Stock Disposition 2016-09-13 5,000 $26.83 327,207 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2016-09-13 5,000 $0.00 5,000 $18.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000 2016-11-30 No 4 M Direct
Footnotes
  1. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 1, 2016.
  2. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  3. Represents weighted average sale price. Actual sale prices ranged from $26.60 to $27.37.
  4. Includes an aggregate of 15,764 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
  5. The option became exercisable as to 25% of the shares on November 30, 2007, and became exercisable as to 1/48th of the shares each full month thereafter.